https://www.selleckchem.com/pr....oducts/z-vad(oh)-fmk
Rationale objective Sodium glucose cotransporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease and prevent heart failure events. However, SGLT2 inhibitors may increase the risk of acute kidney injury (AKI). Our objective was to assess whether SGLT2 inhibitor use, compared to all other glucose lowering drugs (oGLD), is associated with increased rates of AKI. Study design Retrospective cohort study. Setting participants Adults in Manitoba, Canada with type 2 diabetes mellitus (T2DM) followed from Ju
Like
Comment
Share
